前列腺癌的免疫治疗。
Immunotherapy for Prostate Cancer.
机构信息
Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York 10032.
Department of Urology, Columbia Medical Center, New York, New York 10032.
出版信息
Cold Spring Harb Perspect Med. 2019 May 1;9(5):a030627. doi: 10.1101/cshperspect.a030627.
Abstract
Immunotherapy with agents that block immune checkpoints is a mainstay of therapy for several common tumor types; so far, prostate cancer is not among those treated using this method. The observed lack of activity in prostate cancer is not due to a lack of testing; several agents have been evaluated both alone and in combination. Although several combination strategies show some promise, it appears likely that a greater understanding of the prostate cancer tumor microenvironment and baseline immune response will be required to optimize future treatment strategies.
摘要
免疫疗法中使用的药物可以阻断免疫检查点，这是几种常见肿瘤类型的主要治疗方法；到目前为止，前列腺癌还没有采用这种方法进行治疗。在前列腺癌中观察到的这种药物缺乏活性并不是因为缺乏测试；已经评估了几种单独使用和联合使用的药物。尽管几种联合策略显示出了一定的前景，但似乎需要更深入地了解前列腺癌肿瘤微环境和基线免疫反应，以优化未来的治疗策略。
相似文献
1
Immunotherapy for Prostate Cancer.前列腺癌的免疫治疗。
Cold Spring Harb Perspect Med. 2019 May 1;9(5):a030627. doi: 10.1101/cshperspect.a030627.
2
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer.肿瘤微环境与前列腺癌和膀胱癌的免疫治疗。
Urol Clin North Am. 2020 Nov;47(4S):e17-e54. doi: 10.1016/j.ucl.2020.10.005.
3
Demystifying immunotherapy in prostate cancer: understanding current and future treatment strategies.揭开前列腺癌免疫治疗的神秘面纱：了解当前和未来的治疗策略。
Cancer J. 2013 Jan-Feb;19(1):50-8. doi: 10.1097/PPO.0b013e31828160a9.
4
Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.将主动免疫疗法与免疫检查点阻断相结合用于晚期前列腺癌的治疗。
Asian J Androl. 2012 Jul;14(4):520-1. doi: 10.1038/aja.2012.45. Epub 2012 May 14.
5
[Immunotherapy for metastatic prostate cancer: do we really need this?].[转移性前列腺癌的免疫疗法：我们真的需要它吗？]
Urologe A. 2012 Jan;51(1):32-8. doi: 10.1007/s00120-011-2740-2.
6
Prostate cancer immunotherapy.前列腺癌免疫疗法。
Clin Cancer Res. 2011 Aug 15;17(16):5233-8. doi: 10.1158/1078-0432.CCR-10-3402. Epub 2011 Jun 23.
7
Recent progress in immunotherapy for urological cancer.泌尿外科癌症免疫治疗的最新进展。
Int J Urol. 2017 Oct;24(10):735-742. doi: 10.1111/iju.13400. Epub 2017 Jun 21.
8
Clinical development of immunotherapy for prostate cancer.前列腺癌免疫疗法的临床开发
Int J Urol. 2017 Sep;24(9):675-680. doi: 10.1111/iju.13397. Epub 2017 Jun 21.
9
Immunotherapy in prostate cancer: review of the current evidence.前列腺癌的免疫疗法：当前证据综述
Clin Transl Oncol. 2015 May;17(5):339-57. doi: 10.1007/s12094-014-1259-6. Epub 2014 Dec 6.
10
Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.前列腺癌免疫疗法，尤其是与雄激素剥夺疗法或放射治疗联合使用时。采用定制的药物基因组学方法来克服免疫疗法对癌症的耐药性。
G Chir. 2017 Sep-Oct;37(5):225-235. doi: 10.11138/gchir/2016.37.5.225.
引用本文的文献
1
Impact of ITH on PRAD patients and feasibility analysis of the positive correlation gene MYLK2 applied to PRAD treatment.肿瘤内异质性对前列腺癌患者的影响以及阳性相关基因MYLK2应用于前列腺癌治疗的可行性分析。
Front Genet. 2025 May 20;16:1589259. doi: 10.3389/fgene.2025.1589259. eCollection 2025.
2
An Integrated Approach Utilizing Single-Cell and Bulk RNA-Sequencing for the Identification of a Mitophagy-Associated Genes Signature: Implications for Prognostication and Therapeutic Stratification in Prostate Cancer.一种利用单细胞和批量RNA测序鉴定线粒体自噬相关基因特征的综合方法：对前列腺癌预后和治疗分层的意义
Biomedicines. 2025 Jan 27;13(2):311. doi: 10.3390/biomedicines13020311.
3
Sigma1 inhibitor suppression of adaptive immune resistance mechanisms mediated by cancer cell derived extracellular vesicles.Sigma1抑制剂对癌细胞衍生的细胞外囊泡介导的适应性免疫抵抗机制的抑制作用。
Cancer Biol Ther. 2025 Dec;26(1):2455722. doi: 10.1080/15384047.2025.2455722. Epub 2025 Jan 26.
4
Mesenchymal stromal cell exosomes for drug delivery of prostate cancer treatments: a review.间充质基质细胞外泌体用于前列腺癌治疗的药物递送：综述
Stem Cell Res Ther. 2025 Jan 23;16(1):18. doi: 10.1186/s13287-025-04133-8.
5
Fc-enhanced anti-CTLA-4 depletes tumor-infiltrating regulatory T cells to augment immune effects of androgen ablation in high-risk prostate cancer.Fc增强的抗CTLA-4可消耗肿瘤浸润调节性T细胞，以增强雄激素剥夺对高危前列腺癌的免疫效应。
medRxiv. 2025 Mar 31:2024.09.09.24313308. doi: 10.1101/2024.09.09.24313308.
6
Convergent alterations in the tumor microenvironment of MYC-driven human and murine prostate cancer.MYC 驱动的人源和鼠源前列腺癌肿瘤微环境中的趋同改变。
Nat Commun. 2024 Aug 28;15(1):7414. doi: 10.1038/s41467-024-51450-2.
7
Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis.癌症相关成纤维细胞通过CCL5-CCR5旁分泌轴促进前列腺癌中的恩杂鲁胺耐药性和PD-L1表达。
iScience. 2024 Apr 4;27(5):109674. doi: 10.1016/j.isci.2024.109674. eCollection 2024 May 17.
8
Distinct mesenchymal cell states mediate prostate cancer progression.不同的间充质细胞状态介导前列腺癌的进展。
Nat Commun. 2024 Jan 8;15(1):363. doi: 10.1038/s41467-023-44210-1.
9
NSUN2 is a glucose sensor suppressing cGAS/STING to maintain tumorigenesis and immunotherapy resistance.NSUN2 是一种葡萄糖传感器，可抑制 cGAS/STING 以维持肿瘤发生和免疫治疗抵抗。
Cell Metab. 2023 Oct 3;35(10):1782-1798.e8. doi: 10.1016/j.cmet.2023.07.009. Epub 2023 Aug 15.
10
The potential role of the microbiota in prostate cancer pathogenesis and treatment.肠道菌群在前列腺癌发病机制和治疗中的潜在作用。
Nat Rev Urol. 2023 Dec;20(12):706-718. doi: 10.1038/s41585-023-00795-2. Epub 2023 Jul 25.
本文引用的文献
1
Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer.无症状或轻度症状转移性去势抵抗性前列腺癌的 PROSTVAC III 期临床试验。
J Clin Oncol. 2019 May 1;37(13):1051-1061. doi: 10.1200/JCO.18.02031. Epub 2019 Feb 28.
2
Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.伊匹单抗联合纳武单抗与AR-V7表达的转移性前列腺癌中的DNA修复缺陷
Oncotarget. 2018 Jun 19;9(47):28561-28571. doi: 10.18632/oncotarget.25564.
3
Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer.前列腺癌原发灶和转移灶中程序性死亡配体 1 表达的综合评估。
Am J Pathol. 2018 Jun;188(6):1478-1485. doi: 10.1016/j.ajpath.2018.02.014. Epub 2018 Mar 22.
4
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.纳武利尤单抗联合伊匹木单抗与舒尼替尼治疗晚期肾细胞癌的比较
N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21.
5
Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.阻断泌尿生殖系统恶性肿瘤中的PD-1/PD-L1：通向免疫及更远的领域
Cancer J. 2018 Jan/Feb;24(1):20-30. doi: 10.1097/PPO.0000000000000302.
6
Clinically Localized Prostate Cancer: AUA/ASTRO/SUO Guideline. Part II: Recommended Approaches and Details of Specific Care Options.临床局限性前列腺癌：AUA/ASTRO/SUO 指南。第二部分：推荐方法和特定治疗方案的详细信息。
J Urol. 2018 Apr;199(4):990-997. doi: 10.1016/j.juro.2018.01.002. Epub 2018 Jan 10.
7
Cancer statistics, 2018.癌症统计数据，2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
8
Inhibitors of the PD-1 Pathway in Tumor Therapy.肿瘤治疗中的 PD-1 通路抑制剂。
J Immunol. 2018 Jan 15;200(2):375-383. doi: 10.4049/jimmunol.1701044.
9
Combining DNA damaging therapeutics with immunotherapy: more haste, less speed.将 DNA 损伤疗法与免疫疗法相结合：欲速则不达。
Br J Cancer. 2018 Feb 6;118(3):312-324. doi: 10.1038/bjc.2017.376. Epub 2017 Nov 9.
10
Myeloid-derived cells in prostate cancer progression: phenotype and prospective therapies.前列腺癌进展中的髓系来源细胞：表型与前瞻性治疗
J Leukoc Biol. 2017 Aug;102(2):393-406. doi: 10.1189/jlb.5VMR1116-491RR. Epub 2017 May 26.
Zotero 插件